Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ALHEMO (concizumab-mtci)
Published Date: 1/15/2025
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to Novo Nordisk for their new rare pediatric disease drug, ALHEMO, approved in December 2024. This voucher helps speed up the review of future medicines, benefiting patients with rare diseases and encouraging companies to develop more treatments. This move affects drug makers and could speed up new medicine approvals, saving time and possibly money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ALHEMO Approved for Hemophilia Prophylaxis
ALHEMO (concizumab-mtci) was approved on December 20, 2024 for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A with FVIII inhibitors and hemophilia B with FIX inhibitors. If you or a child in your care is in those groups, ALHEMO is an FDA‑approved treatment option as of that date.
Priority Review Voucher Issued to Sponsor
The FDA issued a Priority Review Voucher under section 529 of the FD&C Act to the sponsor of the ALHEMO application (manufactured by Novo Nordisk, Inc.). The notice states ALHEMO met the criteria for a rare pediatric disease priority review voucher following its approval on December 20, 2024.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-18533, The RBB Fund Trust and Millburn Ridgefield LLC
2026-18536, Self-Regulatory Organizations; Texas Stock Exchange LLC; Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change To Amend Exchange Rule 13.003 Related to Proxy Voting
2026-18530, Fortress Investment Group LLC, et al.-Intra-Corporate Family Transaction Exemption
2026-18605, Emran Mohammad, RN, APRN, CNP; Decision and Order
2026-18597, Craig Cohen, DPM; Decision and Order
2026-18599, Cheryl White, N.P.; Decision and Order
Previous / Next Documents
Previous: 2025-00749, Qualification of Drivers; Exemption Applications; Implantable Cardioverter Defibrillators (ICDs)
The FMCSA got requests from two people with special heart devices called ICDs who want to drive big commercial trucks across state lines. Normally, folks with certain heart problems can’t drive these trucks, but if these exemptions are approved, these drivers could hit the road again. You’ve got until February 14, 2025, to share your thoughts—no money changes yet, just a chance to speak up!
Next: 2025-00752, Arts Advisory Panel Meetings
The National Endowment for the Arts is holding four online meetings to review and decide on grant applications for jazz fellowships, arts education, and international arts activities. These meetings happen between February and March 2025 and are closed to the public because they involve private financial discussions. Artists, educators, and organizations applying for funding should watch these dates closely as decisions could impact their support.